Revolutionizing Precision Medicine with AI-Powered Platforms
Welcome to DeepTarget Biotherapeutics
DeepTarget Bio is a biotechnology company advancing therapeutics for fibrosis and cancer through disease-specific targets, differentiated MOAs, and innovative modalities. Our cutting-edge AI-powered platform propels end-to-end pipeline development with high efficiency and success rates, accelerating from groundbreaking discovery through clinical trials and into transformative therapies.
Our Unique Approach
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
- Specifically Target Pathogenic Fibrosis Drivers & Effectors
- Shift from Passive Fibrosis Suppression to Active Disease Reversal
- Organ-Agnostic Antifibrotic Platform
Cutting Edge Therapeutics Design
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
- BiME™: Bispecific Macrophage Engager
- TSI™: Bi-/Tri-Specific Immune Modulator
- ICE™: Next-Generation Immune Cell Engager
- In Vivo Cell Therapy
Proprietary Multi-Agentic AI System
Transformative Therapy for Fibrosis
Proprietary Multi-Agentic AI System
The DeepTarget AI system, DTB.AI™, is a Large Reasoning Model (LRM), combining Inverse Reinforcement Learning and Reinforcement Learning with a human-in-the-loop framework, leveraging domain expertise feedback from our experienced drug developers.
Our Mission
Deliver differentiated therapies that address the underlying drivers of diseases with high unmet medical need
Our Expertise
Our leadership team brings deep pharmaceutical experience from Merck, Amgen, Regeneron, Teva, and Boehringer Ingelheim, with a proven track record across end-to-end drug development. Collectively, the team has contributed to 60+ INDs and 10+ BLAs/MAAs.